Mackie Research Capital resumed coverage of WeedMD (TSXV:WMD) and raised its price target to $4 from $3 after the company completed a $34.5-million offering of units. The stock closed at $2.60 on Jan. 16.Read More
Leerink initiated coverage of Aclaris Therapeutics (NASDAQ:ACRS) with an “outperform” rating and $54 price target. The stock closed at $28.04 on Monday.Read More
GeneNews (TSX:GEN) has entered into a partnership agreement with closely-held NueHealth, which delivers value-based healthcare solutions and connects patients directly to physicians through integrated provider networks.
Patients who access healthcare through NueHealth's provider networks will now be able to take advantage of three different screening tests: ColonSentry, earlyCDT-Lung and Prostate Health Index, which provide early risk stratification of colorectal, lung and prostate cancers.Read More
Roth Capital Partners has launched coverage of Recro Pharma (NASDAQ:REPH) with a “buy” rating and a $24 price target. The stock closed at $9.31 on Thursday.
“The impetus for our buy rating on Recro shares is the upside potential of the pain management pipeline combined with the downside protection from the manufacturing business,” writes analyst Scott Henry.Read More
Roth Capital Partners lowered its price target for “buy-rated” GenVec (NASDAQ:GNVC) to $2 from $8, even though the FDA lifted the clinical hold on CGF166, being run worldwide by partner Novartis. The stock closed at 60 cents on Friday.
“This is an important milestone for the GenVec as CGF166 could be the first gene therapy approved for hearing loss,” writes analyst Joseph Pantginis. New patients will be entering cohort 4 in the dose escalation phase and the study is still expected to be complete in 2017.Read More